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Abstract
Background
Cancer chemotherapy-associated febrile neutropenia (FN) is a common condition that is
deadly when bacteremia is present. Detection of bacteremia depends on culture, which
takes days, and no accurate predictive tools applicable to the initial evaluation are available.
We utilized metabolomics and transcriptomics to develop multivariable predictors of bacter-
emia among FN patients.
Methods
We classified emergency department patients with FN and no apparent infection at presen-
tation as bacteremic (cases) or not (controls), according to blood culture results. We
assessed relative metabolite abundance in plasma, and relative expression of 2,560 immu-
nology and cancer-related genes in whole blood. We used logistic regression to identify mul-
tivariable predictors of bacteremia, and report test characteristics of the derived predictors.
Results
For metabolomics, 14 bacteremic cases and 25 non-bacteremic controls were available for
analysis; for transcriptomics we had 7 and 22 respectively. A 5-predictor metabolomic
model had an area under the receiver operating characteristic curve of 0.991 (95%CI:
0.972,1.000), 100% sensitivity, and 96% specificity for identifying bacteremia. Pregneno-
lone steroids were more abundant in cases and carnitine metabolites were more abundant
in controls. A 3-predictor gene expression model had corresponding results of 0.961 (95%
CI: 0.896,1.000), 100%, and 86%. Genes involved in innate immunity were differentially
expressed.
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Conclusions
Classifiers derived from metabolomic and gene expression data hold promise as objective
and accurate predictors of bacteremia among FN patients without apparent infection at pre-
sentation, and can provide insights into the underlying biology. Our findings should be con-
sidered illustrative, but may lay the groundwork for future biomarker development.
Introduction
Bacteremia due to chemotherapy-associated febrile neutropenia (FN) is one of the most deadly
oncologic emergencies, with mortality rates of up to 50%.[1, 2] Therefore, presumptive broad-
spectrum antibiotic treatment is recommended for all FN patients within 1 hour of onset of symp-
toms, and the vast majority are admitted to the hospital.[3–6] However, fewer than 25% of FN
patients are found to have bacteremia.[1, 3, 4] Antibiotic treatment carries risks including C. diffi-
cile colitis, selection of drug-resistant strains, drug toxicity, allergic reactions, and drug-drug inter-
actions, while hospitalization confers risks of acquisition of nosocomial pathogens, exposure to
medical errors, catheter-associated infections, thromboembolism, and financial burdens.[3, 4, 7–9]
Currently, detection of bacteremia depends on culture, which rules out bacteremia only
after several days; too late to inform initial decisions regarding hospitalization and therapy.
Guidelines recommend that initial treatment decisions be based on clinical evaluation includ-
ing the Multinational Association for Supportive Care in Cancer (MASCC) score.[4, 10] How-
ever, this score was not designed to detect bacteremia, and is insufficiently accurate even for its
intended use, prediction of safe discharge, with a negative predictive value for complications
of only 83%.[11] Consequently, many clinicians do not rely on it, admitting all FN patients by
default.[5, 6] A newer score, the Clinical Index of Stable Febrile Neutropenia, is also inade-
quate, with a 9.1% rate of bacteremia in the low-risk group.[12] Similarly, PCR for bacterial
DNA, and measurement of host markers such as procalcitonin, lack sufficient sensitivity.[13–
15] Objective tests are needed to detect bacteremia during the initial evaluation, so that
patient-specific management strategies can be employed.
High throughput ‘omics’ profiling is a powerful tool for the discovery of biomarkers for var-
ious conditions, including infectious diseases.[16] Metabolomics, which provides an integrated
profile of biological status, reflecting the “net results” of genetic, transcriptomic, proteomic,
and, environmental interactions, represents a particularly powerful research tool.[17] Differ-
entially-abundant metabolites may be utilized as biomarkers to discriminate between those
with and without bacteremia.[18, 19] By integrating gene-expression data with metabolomic
data, we can identify changes in upstream regulators of the metabolites of interest, strengthen-
ing pathway analyses and facilitating deeper understanding of underlying biology.[20, 21]
The aim of this study, was to develop methods for the development of omic biomarkers
that can accurately identify bacteremia among FN patients without apparent infection. Eventu-
ally, we hope to build upon the most promising results from this project to develop a multivar-
iable biomarker that can be advanced into a test for routine clinical use, whilst informing on
underlying biology.
Methods
Study population
Between October 2015 and October 2016, we recruited patients with fever (defined as a single
oral temperature38.3˚C or an oral temperature38˚C sustained over a 1-hour period)[4,
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10] and FN (defined as<1000 neutrophils/μL2), from the Brigham and Women’s Hospital
emergency department (receiving emergency department for the Dana Farber Cancer Insti-
tute). All patients had detailed clinical evaluations including history, physical exam, chest X-
ray, urinalysis, and, blood and urine cultures. Information on antibiotic use in the 24 hours
prior to blood collection was also recorded. Patients presenting with focal bacterial infection
(pneumonia, skin infection, urinary tract infection, intra-abdominal infection) or evidence of
sepsis in the judgment of two investigators were excluded, as the goal of this study was to find
an indicator of bacteremia in patients without initially-detectable bacterial infection. Trained
research assistants screened for eligible patients between the hours of 7am and 11pm daily.
Once subjects were identified, they collected two blood samples (in PAXgene RNA preserva-
tion tubes and lithium heparin tubes) and clinical data. Two investigators then independently
categorized each subject, relying upon the diagnostic investigation conducted as part of rou-
tine care and the recommendations of the Infectious Diseases Society of America and the
American Society of Clinical Oncology.[4, 10, 22] The investigators placed each subject into
one of three categories: (i) No evidence of focal infection or sepsis at presentation and ulti-
mately found to have been bacteremic (cases), (ii) No evidence of focal infection or sepsis at
presentation and ultimately found not to have been bacteremic (controls), or (iii) Evidence of
focal infection or sepsis at presentation (excluded),. The Partners Health Care Human Subjects
Research Committee approved this study, and all participants provided written informed
consent.
Metabolomic and gene expression profiling
Mass spectrometry-based metabolomic profiling was performed on plasma samples by Meta-
bolon, Inc. (Durham, NC), as described previously [23, 24] Briefly, the global biochemical pro-
filing analysis was composed of four unique arms covering a broad range of the metabolome;
(i) reverse-phase chromatography positive ionization methods optimized for hydrophilic com-
pounds (LC–MS Pos Polar) and (ii) hydrophobic compounds (LC–MS Pos Lipid); (iii)
reverse-phase chromatography with negative ionization conditions (LC–MS Neg), and (iv) a
HILIC chromatography method coupled to negative (LC–MS Polar). Metabolites were anno-
tated based on an iterative process of matching on mass to charge ratio, retention time and
spectral fragmentation signature, followed by manual curation to confirm biochemical identi-
fication. Further details are provided in S1 Methods.
RNAseq could not be used in this population due to the paucity of white blood cells.
We used EdgeSeq from HTG Molecular, Inc (Tucson, AZ).[25] to quantify the expression of
2,560 genes relevant to cancer and immunology. This technology does not require an RNA
isolation step. The panel of genes was chosen by an iterative process of literature review and
key opinion leader feedback, and included 24 gene groups and pathways.[26]. Analysis was
performed as described previously [25, 26]. Briefly, the EdgeSeq assay couples quantitative
nuclease protection with next-generation sequencing. After allowing nuclease protection
probes (NPPs) to hybridize to their target RNAs, S1 nuclease is added to remove excess unhy-
bridized NPPs and RNA, leaving behind only NPPs hybridized to their target RNAs, resulting
in a stoichiometric conversion of target RNA to the NPPs and producing a 1:1 ratio of NPP to
RNA. The quantitative nuclease protection steps are automated on the EdgeSeq processor, fol-
lowed by PCR to add sequencing adaptors and tags. The labeled samples are pooled, cleaned,
and sequenced on a next-generation sequencing platform using standard protocols. The
resulting data are processed and reported by EdgeSeq parsing software. Further details are pro-
vided in S1 Methods.
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Quality control and data processing
Metabolomics. We used a previously published [27] QC and processing pipeline to clean
the metabolomic dataset. We excluded metabolites with zero abundance in all samples, then
imputed all remaining missing observations with half the lowest detected value for that metab-
olite. We considered metabolites with zero variance uninformative and excluded them. We
then pareto scaled and log-transformed the data.
Gene expression. We performed data processing and normalization according to Edge-
Seq manufacturer’s standards.[25, 26] Data were transferred from the Illumina MiSeq
sequencer as demultiplexed FASTQ files, with one file per original well of the 96-well sample
plate. The HTG EdgeSeq Parser was used to align the FASTQ files to the probe list to collate
the data, which were then median-normalized.[28]
Statistical analysis
Prediction. We used unsupervised principal components analysis (PCA) to assess the
ability of the metabolome and gene expression data to discriminate cases (with bacteremia)
from controls (without bacteremia). We further interrogated these plots to determine if other
clinical factors may be driving the metabolomic profiles. We then used supervised partial least
squares discriminant analysis (PLS-DA) to assess predictive accuracy for bacteremia. Next, we
attempted to identify metabolomics and genetic predictive profiles using two approaches; (i)
We used independent logistic regression models adjusting for age, sex, body mass index
(BMI), and, tumor type (solid/liquid) to identify the metabolites most strongly associated with
the presence or absence of bacteremia. Differential gene expression analysis was used for the
gene expression data. (ii) We employed least absolute shrinkage and selection (LASSO) spar-
sity-inducing logistic regression to identify more parsimonious metabolomic and genomic
predictors. We ran two logistic models; one containing all metabolites, and one containing all
genes to identify the subset of metabolites and genes retained in the models. These were then
selected as the predictors. We used the lambda that produced the minimum mean cross vali-
dated error.[29]
We then created metabolite and gene summary scores based on (i) the first principal com-
ponent of metabolites/expressed genes identified as differentially abundant in cases vs. con-
trols in the regression models; and (ii) metabolites/genes selected in the LASSO model. We
used receiver operating characteristic (ROC) curve analysis to evaluate the predictive ability of
these summary scores for bacteremia, and employed the method of DeLong to compare areas
under the ROCcurves for the different scores.[30] We determined a cutoff that maximized sen-
sitivity, and calculated specificity at this cutoff. The currently recommended approach to risk
stratification is to classify a patient as high-risk if the MASCC score is <21 or if any of the
Infectious Diseases Society of America/American Society of Clinical Oncology high risk crite-
ria are met.[3, 4] While this approach to risk stratification was not designed to detect bacter-
emia, no other method currently exists to classify these patients. Therefore, we compared the
accuracy of this classifier as a predictor of bacteremia to the accuracy of our omic predictors of
bacteremia.
Analysis of underlying biology. We explored metabolic pathways using MetaboAnalyst
(http://www.metaboanalyst.ca/), which takes both overrepresentation and pathway topology
into account, assigning more weight to metabolites that form key components or ‘hubs’ of spe-
cific pathways. For gene expression, we performed gene set enrichment analysis using the g.
GOSt tools from the g.profiler package (http://biit.cs.ut.ee/gprofiler/).
In order to combine the findgins from the metabolomics and genetic analysis, we used
IMPaLA (Integrated Molecular Pathway Level Analysis; http://impala.molgen.mpg.de/) [31]
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to identify pathways that were jointly dysregulated at the level of both metabolites and gene
expression. IMPaLA performs over-representation analysis considering both genes and metab-
olites to provide a combined pathway p-value as well as a q-value that accounts for multiple
testing.
Results
Study population
Metabolomic profiling was performed for 58 subjects who were classified by two investigators
with no disagreements. Fourteen (24%) had bacteremia (cases); 25 (43%) had no evidence of
bacterial infection (controls); and, 19 (33%) had evidence of a focal infection without bacter-
emia (excluded from analysis), resulting in a total of 39 analyzed subjects (Table 1). Gene
expression data were available for only seven of the cases and 21 of the controls, due to logisti-
cal issues. A further control had gene expression profiling only. In total seven cases and 22
controls were included in the gene expression analysis.
Cases demonstrated a significantly higher maximum temperature, lower neutrophil and
lymphocyte counts, and a lower MASCC score as expected. Patients with both solid and liquid
tumors originating from a variety of organs were included. Cases were more likely to have a
liquid tumor than controls, but there was no significant difference in tumor site. Antibiotic
treatment was initiated prior to sample collection in 85% of subjects; there was no significant
difference in the proportion of cases and controls who received antibiotics (Table 1).
Metabolomics
A total of 1,296 metabolites were measured. After exclusion of metabolites that were missing
for all subjects and those with no variance across the population, 1,204 metabolites remained
for analysis. These included amino acids, carbohydrates, lipids, nucleotides, vitamins, peptides,
energy metabolites, and 163 xenobiotics. PCA based on all 1,204 metabolites revealed separa-
tion between cases and controls along the first two components which together explained 27%
of the variance in the data (Figure A in S1 File). To determine if these metabolomic profiles
were driven by other clinical factors we also interrogated the PCA plot in terms of tumor type
(liquid or solid); tumor site and antibiotic use prior to blood draw. Among the bacteremic
cases only, we also explored the bacteria type subsequently identified in the culture (Gram-
positive, Gram-negative or both). These plots indicated no clustering based on any of these
variables; and therefore provided no evidence that these factors were driving the metabolomic
profiles (Figure B in S1 File). Regression models confirmed that both PC1 (p = 8.8x10-4) and
PC2 (p = 0.024) were significantly associated with case status.
Partial least squares discriminant analysis (Fig 1) suggested that a metabolomic classifier
could distinguish between cases and controls, with R2 = 0.650, and a cross-validated Q2 of
0.410 for the first component. Interrogation of the variable importance in the projection plot
(VIP; a measure of the relative importance of each feature in the PLS-DA) identified 17α-
hydroxypregnanolone glucuronide, estrone 3-sulfate, 5α-pregnan-3, 20β-diol disulfate and
pregn steroid monosulfate (C21H3405S) as the top metabolites driving the discrimination.
Carnitines, also had high VIP scores.
Permutation testing revealed that the model was not robust (p = 0.366). Therefore, a refined
discriminatory profile was sought by identifying metabolites significantly associated with bac-
teremia using multivariable logistic regression. After adjustment for age, sex, BMI and, tumor
type (liquid or solid), a total of 177 metabolites were significant at p<0.05 and 19 were signifi-
cant at a p<0.01 (Fig 2 and Table A in S1 File). A majority of the significant metabolites were
lipids. We observed upregulation of pregnenolone steroids and downregulation of carnitine
Omics and bacteremia
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metabolites among bacteremia cases. The relative metabolite intensities in cases and controls
for the top eight upregulated and top eight downregulated metabolites are shown in Figure C
in S1 File. Pathway analysis identified six metabolic pathways that were enriched among these
significant metabolites: pyrimidine metabolism (p = 0.002), ascorbate and aldarate metabolism
(p = 0.003), purine metabolism (p = 0.017), sphingolipid metabolism (p = 0.018), pantothenate
metabolism (p = 0.022) and valine, leucine and isoleucine metabolism (p = 0.022).
Table 1. Baseline characteristics of the study population.
Cases (n = 14) Controls (n = 25) p-value
Sex Female 4 28.6% 13 52.0% 0.193
Male 10 71.4% 12 48.0%
Age (years) mean (SD) 55.1 (11.6) 47.0 (16.4) 0.082
BMI mean (SD) 26.4 (2.7) 25.3 (4.3) 0.310
Tmax (oF) mean (SD) 102.2 (0.8) 101.3 (0.8) 2x10-3
Absolute Neutrophil Count mean (SD) 0.12 (0.22) 0.35 (0.31) 0.012
Absolute Lymphocyte Count mean (SD) 0.21 (0.20) 0.56 (0.51) 0.005
MASCC risk score mean (SD) 15.0 (4.3) 18.1 (3.8) 0.032
MASCC high risk 21 (low risk) 1 7.1% 8 32.0% 0.120
<21 (high risk) 13 92.9% 17 68.0%
ASCO high 14 100.0% 22 88.0% 0.540
low 0 0.0% 3 12.0%
IDSA high 13 92.9% 20 80.0% 0.391
low 1 7.1% 5 20.0%
Tumor type liquid 12 85.7% 11 44.0% 0.017
solid 2 14.3% 14 56.0%
Cancer typea Breast 0 0.0% 3 12.0% 0.441
Esophageal 0 0.0% 2 8.0%
Gynecological 1 7.1% 2 8.0%
Hematological 12 85.7% 10 40.0%
Lung 0 0.0% 1 4.0%
Male reproductive 0 0.0% 2 8.0%
Other 1 7.1% 4 16.0%
Skin 0 0.0% 1 4.0%
Antibiotics prior to blood drawb Yes 14 100.0% 19 76.0% 0.071
No 0 0.0% 6 24.0%
Organismc Gram-Negative 8 57.1% -
Gram-Positive 5 35.7% -
Both 1 7.1% -
Gene Expression Datad Available 7 52.9% 21 84.0% 0.033
Indicates a significant difference between cases and controls at a 95% confidence level
Tmax–maximum temperature
MASCC–Multinational Association for Supportive Care in Cancer
ASCO–American Society of Clinical Oncology binary classifier
IDSA–Infectious Diseases Society of America binary classifier
SD–Standard deviation
a Information on cancer type was not available for one control
b The patient received antibiotics in the 24 hours prior to blood draw
c Type of bacteria ultimately identified in the culture samples from bacteremic cases
dTranscriptomic analysis was conducted on 7 cases and 22 controls–one of these controls did not have metabolomic profiling available
https://doi.org/10.1371/journal.pone.0197049.t001
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We generated a summary score based on the first principal component of the 177 metabo-
lites, and used ROC curve analysis to explore the discriminatory ability of this score (Fig 3).
To identify the most parsimonious model, we then used LASSO regression, and identified a
five-metabolite score. The AUCs of the two currently available clinical classifiers; MASCC and
MASCC plus an indicator of risk (“high-risk” classifier), were 0.624 (95%CI: 0.508–0.741) and
0.540 (95%CI: 0.486–0.594), respectively. Both metabolite scores significantly out-performed
these classifiers with AUCs of 0.969 (95%CI: 0.918–1.000) (p dif MASCC classifier = 2.3x10-8;
p dif high risk classifier <2.2x10-16) for the standard logistic score and 0.991 (95%CI: 0.972–
1.000) (p dif MASCC classifier = 8.0x10-10; p dif high risk classifier <2.2x10-16) for the LASSO
score. Furthermore, while the sensitivity of the binary MASCC and “high risk” classifiers was
high (93% and 100%, respectively), the corresponding specificities were only 32% and 8%. In
contrast, at the cutoff required to achieve 100% sensitivity, the specificity of the standard logis-
tic classifier was 88%, and the parsimonious LASSO classifier was 96% (Table 2).
Sensitivity analyses. A sensitivity analysis additionally adjusting for antibiotic use in the
24 hours prior to blood draw identified 118 significant metabolites; 112 (95%) of which were
also among the 177 identified in the original analyses. We ran a further sensitivity analysis
adjusting for the difference between absolute neutrophil and absolute leukocyte count. Again,
of the 169 metabolites that retained significance in this model, 159 (94%) were among the orig-
inal 177 metabolites., demonstrating the robustness of these findings.
Fig 1. Partial least square discriminant analysis demonstrating metabolomic differences in bacteremia cases (n = 14) and controls
(n = 25). The first two components and the corresponding percentage of the total variance in the metabolome explained by these two
components are presented.
https://doi.org/10.1371/journal.pone.0197049.g001
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Similarly, we wanted to determine whether the type of bacteria (Gram-negative or Gram-
positive) responsible for the bacteremia influenced the results. Although the numbers were too
small (n = 5 cases) for the model to converge when considering only at Gram-positive bacteria,
we identified 129 metabolites significantly associated with Gram-negative bacteria (n = 8
cases). Ninety-nine (77%) of these were also among the 177 metabolites; including many of the
most significant hits such as the carnitines and pregnenolone steroids. Furthermore, when
comparing the relative levels of these top metabolites in controls versus cases stratified by
Gram-status, both the Gram-negative and Gram positive bacteria cases were distinct from the
controls (Figure D in S1 File). This again suggests that case-control status rather than bacteria
type among the cases was the biggest driver of the differential metabolite abundance.
Gene expression profiling
Evidence of separation in the gene expression profile of cases (n = 7) and controls (n = 22) was
also suggested by a PCA model based on 2,560 mRNAs. The PLS-DA model (Fig 4) resulted in
an R2 of 0.60, but a Q2 of only 0.09, and again permutation testing indicated that this model
Fig 2. Association between metabolites and bacteremia using a multivariable logistic regression model after adjustment for age, sex, BMI and tumor type (liquid
or solid). Metabolites are colored according to their super pathway assignment and top metabolites are named; nominal significance levels of 95% and 99% are indicated
with dashed red line; the x axis represents the strength of the association and the y-axis the significance–metabolites to the right of the plot are at higher levels in cases
than controls, metabolites to the left are at higher levels among the controls.
https://doi.org/10.1371/journal.pone.0197049.g002
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was not robust (p = 0.974). Differential expression analysis identified 150 nominally significant
genes, of which three were significant at p<0.01 (Fig 5). The top genes included CTSS
(p = 0.005), FGL2 (p = 0.006), LYZ (p = 0.009), PPBP (p = 0.010), CYBB (p = 0.011) and CD86
(p = 0.011). The expression levels of the top eight over-expressed genes and the top eight
under expressed-genes in cases versus controls are shown in Figure D in S1 File. G.profiler
analysis determined that the significant genes were enriched for 24 biological terms, including
a number relating to vesicle mediated transport, and cytokines (Table B in S1 File). When
LASSO regression was employed, only three genes were retained in the model: RAD18, which
encodes a DNA repair protein, MAPKAPK3, a kinase activated in response to cellular stress
and JAG1, which has a reported role in hematopoiesis. Sensitivity analyses were not performed
on the gene-expression data due to sample size limitations.
In this subset of patients the AUC for the MASCC classifier was 0.610 (95%CI: 0.437–0.784)
and for the high-risk classifier0.546 (95% CI: 0.484–0.607). Again, the omics-based scores out-
performed these metrics. The summary score based on the 150 genes had an AUC of 0.974
(95%: 0.923–1.000) (p dif MASCC classifier = 1.21x10-4; p dif high risk classifier< 2.20x10-16),
Fig 3. Receiver operating characteristic curves showing the performance of metabolomic (logistic and LASSO) predictors compared to existing clinical
(MASCC and high-risk) classifiers. AUC–Area under the receiver operating characteristic curve.MASCC binary classifier-Multinational Association for
Supportive Care in Cancer score categorized into <21 (high risk) and21(low risk). High risk binary classifier- defines a patient as high risk if the MASCC score is
<21 or if any of the Infectious Diseases Society of America/American Society of Clinical Oncology high risk criteria are met. Logistic score–summary score based on
the 137metabolites associated with bacteremia under a multivariable logistic regression model. LASSO score–summary score based on the sevenmetabolites
associated with bacteremia under a penalized LASSOmodel.
https://doi.org/10.1371/journal.pone.0197049.g003
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Table 2. Sensitivity and specificity of the metabolomic and gene expression classifiers compared to existing clinical predictors in terms of area under the curve, sen-
sitivity and specificity.
Classifier AUC 95%CI Sensitivity Specificity
Metabolomic Data
MASSC21 0.624 (0.508, 0.741) 93% 32%
High Risk Classification 0.54 (0.486, 0.594) 100% 8%
Logistic Score optimal cutoff 0.969 (0.918, 1.000) 100% 88%
LASSO Score optimal cutoff 0.991 (0.972, 1.000) 100% 96%
Gene Expression Data
MASSC21 0.61 (0.437, 0.784) 89% 36%
High Risk Classification 0.546 (0.484, 0.607) 100% 9%
Logistic Score optimal cutoff 0.974 (0.926 1.000) 100% 86%
LASSO Score optimal cutoff 0.961 (0.896, 1.000) 100% 86%
AUC–Area under the receiver operating characteristic curve
MASCC binary classifier–Multinational Association for Supportive Care in Cancer score categorized into <21 (high risk) and21(low risk)
High risk binary classifier–defines a patient as high-risk if the MASCC score is <21 or if any of the Infectious Diseases Society of America/American Society of Clinical
Oncology high risk criteria are met
Logistic and LASSO score cutoffs were chosen to obtain 100% sensitivity
https://doi.org/10.1371/journal.pone.0197049.t002
Fig 4. Partial least square discriminant analysis demonstrating differential gene expression in bacteremia cases
(n = 9) and controls (n = 21). Gene expression profiles based on 2560 genes quantified using EdgeSeq; the first two
components and the corresponding percentage of variances in the gene expression profile explained by these two
components are presented.
https://doi.org/10.1371/journal.pone.0197049.g004
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while the AUC for a model including RAD18 (p in logistic model = 0.017), MAPKAPK3 (p in
logistic model = 0.014) and JAG1 (p in logistic model = 0.017) as predictors was 0.961 (95%CI:
0.896 1.000) (p dif MASCC classifier = 5.51x10-6; p dif high risk classifier <2.20x10-16) (Fig 6).
The binary MASCC and high-risk classifiers in this gene expression subpopulation were sensi-
tive (89% and 100%, respectively), but had low specificities (36% and 9%). In contrast, with
100% sensitivity, the specificities was 86% for both our standard logistic and LASSO genomic
classifiers (Table 2).
Fig 5. Association between gene expression and bacteremia using a logistic regression model. Top genes are names; nominal significance
levels of 95% and 99% are indicated with dashed red line; the x axis represents the strength of the association and the y-axis the significance–
genes to the right of the plot are more highly expressed in cases than controls, genes to the left are more highly expressed among the controls.
https://doi.org/10.1371/journal.pone.0197049.g005
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Integrative analysis
When we combined the metabolomic and gene expression data into a single data set, there
were too few observations to demonstrate predictive ability, because we had both datasets for
only 28 participants. This caused the number of parameters to exceed the number of observa-
tions by too wide a margin for our models to converge on a solution. However, integrative
analysis using IMPaLA revealed that a number of the genes and metabolites independently
identified as significant in the previous analyses are involved in the same biological pathways
and processes (Table 3). Forty eight pathways were identified as being differentially perturbed
in terms of both metabolomics and gene expression (joint q-value<0.05). These included path-
ways relating to the immune system (joint q-value = 6.29x10-8) insulin regulation (including
the Insulin receptor signaling cascade; joint q-value = 6.29x10-8, IRS-related events triggered
by IGF1R;joint q-value = 4.33x10-3), the MAPK signaling pathway (joint q-value = 8.38x10-3)
Fig 6. Receiver operating characteristic curves showing the performance of gene expression based (logistic and LASSO) predictors compared to existing
clinical (MASCC and high-risk) classifiers. AUC–Area under the receiver operating characteristic curve. MASCC binary classifier–Multinational Association
for Supportive Care in Cancer score categorized into<21 (high risk) and21(low risk). High risk binary classifier–defines a patient as high risk if the MASCC
score is<21 or if any of the Infectious Diseases Society of America/American Society of Clinical Oncology high risk criteria are met. Logistic score–summary
score based on the 153 genes associated with bacteremia under a logistic regression model. LASSO score–summary score based on the 2 genes associated with
bacteremia under a penalized LASSO model.
https://doi.org/10.1371/journal.pone.0197049.g006
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Table 3. Pathways differentially enriched at metabolomic and transcriptomic levels.
Process # Overlapping
Genes
Genetic
p-value
Genetic q-
value
# Overlapping
metabolites
Metabolomic p-
value
Metabolomic q-
value
Joint
p-value
Joint
q-value
Immune System 52 1.28E-
10
5.51E-07 5 8.39E-03 3.52E-01 3.06E-
11
6.29E-
08
Innate Immune System 37 3.36E-
08
2.90E-05 3 1.08E-01 8.46E-01 7.40E-
08
7.61E-
05
Signaling by NGF 16 1.90E-
05
3.53E-03 4 1.56E-03 2.01E-01 5.44E-
07
3.73E-
04
Cytokine Signaling in Immune system 20 3.36E-
07
1.45E-04 1 2.83E-01 1.00E+00 1.64E-
06
6.73E-
04
Signaling by EGFR 15 2.12E-
06
7.64E-04 2 6.94E-02 7.59E-01 2.47E-
06
7.25E-
04
PI3K-Akt signaling pathway—Homo
sapiens (human)
15 4.82E-
06
1.39E-03 1 6.43E-02 7.26E-01 4.95E-
06
1.27E-
03
HIF-1 signaling pathway—Homo sapiens
(human)
7 1.37E-
04
9.67E-03 3 3.73E-03 3.16E-01 7.88E-
06
1.80E-
03
Transmembrane transport of small
molecules
7 5.36E-
01
1.00E+00 15 1.20E-06 4.80E-03 9.84E-
06
1.97E-
03
Chemokine signaling pathway—Homo
sapiens (human)
11 6.61E-
06
1.72E-03 1 1.05E-01 8.26E-01 1.05E-
05
1.97E-
03
Insulin receptor signaling cascade 12 2.05E-
05
3.53E-03 2 4.11E-02 6.14E-01 1.26E-
05
2.16E-
03
Integrated Breast Cancer Pathway 6 8.33E-
05
7.26E-03 2 1.53E-02 4.04E-01 1.86E-
05
2.83E-
03
Adaptive Immune System 20 4.70E-
04
2.23E-02 4 2.82E-03 2.55E-01 1.92E-
05
2.83E-
03
NGF signaling via TRKA from the plasma
membrane
14 2.14E-
05
3.55E-03 2 7.57E-02 7.59E-01 2.32E-
05
3.18E-
03
Signal Transduction 45 3.49E-
04
1.80E-02 10 5.30E-03 3.24E-01 2.63E-
05
3.38E-
03
Signaling by Insulin receptor 12 5.19E-
05
6.77E-03 2 4.11E-02 6.14E-01 3.00E-
05
3.42E-
03
Downstream signal transduction 13 3.18E-
05
4.91E-03 2 6.33E-02 7.26E-01 2.84E-
05
3.42E-
03
DAP12 signaling 13 3.64E-
05
5.42E-03 2 6.33E-02 7.26E-01 3.22E-
05
3.49E-
03
Central carbon metabolism in cancer—
Homo sapiens (human)
6 9.07E-
05
7.26E-03 3 4.24E-02 6.14E-01 5.18E-
05
4.33E-
03
IRS-mediated signaling 11 9.00E-
05
7.26E-03 2 4.11E-02 6.14E-01 5.00E-
05
4.33E-
03
IRS-related events triggered by IGF1R 11 1.04E-
04
8.01E-03 2 4.11E-02 6.14E-01 5.70E-
05
4.33E-
03
IGF1R signaling cascade 11 1.04E-
04
8.01E-03 2 4.11E-02 6.14E-01 5.70E-
05
4.33E-
03
Signaling by Type 1 Insulin-like Growth
Factor 1 Receptor (IGF1R)
11 1.08E-
04
8.01E-03 2 4.11E-02 6.14E-01 5.89E-
05
4.33E-
03
DAP12 interactions 13 5.92E-
05
6.91E-03 2 6.33E-02 7.26E-01 5.06E-
05
4.33E-
03
Signaling by PDGF 13 6.91E-
05
7.18E-03 2 6.33E-02 7.26E-01 5.84E-
05
4.33E-
03
GPCR signaling-G alpha s PKA and ERK 12 7.06E-
05
7.18E-03 1 8.48E-02 7.59E-01 7.80E-
05
5.53E-
03
Diseases of signal transduction 12 2.05E-
05
3.53E-03 1 3.30E-01 1.00E+00 8.70E-
05
5.81E-
03
(Continued)
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and multiple pathways involved in the signaling processes necessary for cell survival, differen-
tiation and apoptosis, (such as signaling by NGF; joint q-value = 3.73x10-45, signaling by
EGFR; joint q-value = 7.25x10-4 andDAP12 signaling; joint q-value = 4.49x10-3).
Table 3. (Continued)
Process # Overlapping
Genes
Genetic
p-value
Genetic q-
value
# Overlapping
metabolites
Metabolomic p-
value
Metabolomic q-
value
Joint
p-value
Joint
q-value
Chemokine signaling pathway 9 8.44E-
05
7.26E-03 1 1.05E-01 8.26E-01 1.12E-
04
7.18E-
03
MAPK Signaling Pathway 8 5.27E-
04
2.42E-02 1 2.19E-02 4.38E-01 1.43E-
04
8.38E-
03
Pathways in cancer—Homo sapiens
(human)
14 1.18E-
04
8.55E-03 2 9.55E-02 8.26E-01 1.40E-
04
8.38E-
03
UMP Synthase Deficiency (Orotic
Aciduria)
3 1.96E-
03
5.47E-02 5 7.26E-03 3.29E-01 1.73E-
04
8.66E-
03
Pyrimidine Metabolism 3 1.96E-
03
5.47E-02 5 7.26E-03 3.29E-01 1.73E-
04
8.66E-
03
MNGIE (Mitochondrial
Neurogastrointestinal Encephalopathy)
3 1.96E-
03
5.47E-02 5 7.26E-03 3.29E-01 1.73E-
04
8.66E-
03
Dihydropyrimidinase Deficiency 3 1.96E-
03
5.47E-02 5 7.26E-03 3.29E-01 1.73E-
04
8.66E-
03
Beta Ureidopropionase Deficiency 3 1.96E-
03
5.47E-02 5 7.26E-03 3.29E-01 1.73E-
04
8.66E-
03
GPCR signaling-cholera toxin 11 1.90E-
04
1.22E-02 1 8.48E-02 7.59E-01 1.94E-
04
9.51E-
03
Ca-dependent events 1 2.82E-
01
8.54E-01 4 5.98E-05 5.40E-02 2.02E-
04
9.68E-
03
Pyrimidine nucleotides nucleosides
metabolism
3 1.94E-
02
2.20E-01 6 9.34E-04 1.49E-01 2.16E-
04
9.86E-
03
Ascorbate and aldarate metabolism—
Homo sapiens (human)
1 2.58E-
01
8.12E-01 5 8.12E-05 5.40E-02 2.47E-
04
1.08E-
02
Metabolism 19 8.04E-
01
1.00E+00 32 3.36E-05 4.46E-02 3.11E-
04
1.33E-
02
PLC beta mediated events 2 9.41E-
02
4.94E-01 4 3.91E-04 1.20E-01 4.12E-
04
1.73E-
02
G-protein mediated events 2 9.75E-
02
5.04E-01 4 3.91E-04 1.20E-01 4.26E-
04
1.75E-
02
Hemostasis 20 6.59E-
05
7.18E-03 1 6.17E-01 1.00E+00 4.52E-
04
1.82E-
02
Disease 15 5.10E-
04
2.37E-02 3 9.87E-02 8.26E-01 5.48E-
04
2.09E-
02
HTLV-I infection—Homo sapiens
(human)
10 5.54E-
04
2.47E-02 1 1.05E-01 8.26E-01 6.24E-
04
2.29E-
02
GPCR signaling-G alpha s Epac and ERK 10 8.33E-
04
3.30E-02 1 8.48E-02 7.59E-01 7.45E-
04
2.60E-
02
SLC-mediated transmembrane transport 4 3.82E-
01
1.00E+00 11 1.98E-04 8.75E-02 7.92E-
04
2.67E-
02
Pyrimidine catabolism 1 1.24E-
01
5.67E-01 5 9.23E-04 1.49E-01 1.15E-
03
3.54E-
02
PKB-mediated events 3 9.52E-
03
1.41E-01 2 1.53E-02 4.04E-01 1.43E-
03
4.21E-
02
Overlapping–indicates gene/metabolite are found both in the named pathway and among the set identified as significantly associated with bacteremia in this population
Enrichment p and q values are provided for the metabolites alone, the genes alone and the joint enrichment
Q-value–p-value adjusted for the false discovery rate
https://doi.org/10.1371/journal.pone.0197049.t003
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Discussion
We have demonstrated methods for discovery of a multi-omics-based predictor for detection
of bacteremia among FN patients without apparent infection. Omic profiles are increasingly
being leveraged as predictive, diagnostic and prognostic biomarkers, and can provide insight
into the underlying biology.[32, 33] Metabolomic and transcriptomic diagnostics have already
been deployed clinically. For example, real-time analysis of the metabolome is a clinical reality,
as exemplified by the iKnife, which performs instantaneous analysis of the mucosal lipidome
to phenotype colorectal cancer during surgery.[34] Similarly, transcriptomics have yielded
diagnostic tests that are approaching clinical implementation for detection of serious bacterial
infection.[35, 36] To our knowledge, this was the first study to develop multi-omic based bio-
markers of bacteremic FN; one prior study used metabolomics alone to investigate infection in
the setting of FN.[37] Our future work will apply these methods to a larger sample size, sepa-
rated into derivation and validation sets, with the goal of developing a clinically-applicable tool
for detection of bacteremia during the initial evaluation.
For detection of bacteremia, the two existing clinical predictors; MASCC and the high-risk
classifier, were sensitive but demonstrated poor specificity. In contrast, although derived from
only a small population, our metabolomic and transcriptomic predictors maintained impres-
sive specificities with 100% sensitivity. These results demonstrate that derivation of omics-
based predictors of bacteremia in the setting of FN is feasible, and justify further research in a
larger sample.
We found that pregnenolone steroids, which are cortisol precursors, were upregulated in
cases relative to controls. Prior research has linked sepsis to an overexpression of cortisol pre-
cursors despite normal cortisol levels, implying decreased activity of 3-beta-hydroxysteroid
dehydrogenase.[38] Carnitines were down-regulated in cases, which is in agreement with pre-
vious evidence for a differential abundance of carnitines in bacteremic compared to non-bac-
teremic patients.[39, 40] L-carnitine has entered clinical trials as a therapeutic agent for
patients with sepsis, and metabolomic analysis has been used to identify the subset of patients
responding.[41] Other pathways involved in amino acid metabolism were also perturbed,
which could relate to the enhanced extraction of amino acids by the liver noted in patients
with sepsis and systemic inflammatory response syndrome.[42] For example, pyrimidine
metabolism was differentially regulated, possibly due to the de novo synthesis of pyrimidines
required for successful proliferation of pathogens in blood.[43] Furthermore, the dysregulation
of the ascorbate and aldarate metabolism pathway may relate to the lower circulating levels of
ascorbate reported in patients with sepsis.[44]
A number of genes showed differential expression between cases and controls. These
included, PPBP, an antimicrobial protein with bactericidal and antifungal activity; CYBB,
which is essential for the microbicidal oxidase system of phagocytes; LYZ, which encodes a
component of the innate immune system that cleaves peptidoglycan bonds in the bacterial cell
wall;,and CD86 and FGL2 which have been associated with severity and worse outcomes in
sepsis[45, 46] These results suggest that a weaker innate immune response might predispose to
bacteremia after depletion of the adaptive immune system by chemotherapy. On a pathway
level, the differentially-expressed genes were enriched for a number biological processes
including some relating to the release of cytokines, supporting the idea of a unique immuno-
logic milieu in FN patients with bacteremia.
Integrative analysis supported the findings of the individual omics analysis, and provided
mechanistic links between the metabolites and genes independently associated with bacter-
emia. For example, MAPK signaling pathways were perturbed. MAPKs play an important role
in the cascade of cellular responses evoked by extracellular stimuli such as pro-inflammatory
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cytokines or physical stress, and they have been shown to be activated in the setting of bacterial
challenge.[47] These integrative results should be viewed with caution due to the limited sam-
ple size, which was constrained by funding. However they do provide a good indication of
potential gene-metabolite relationships, and a demonstration that in a larger sample, dysregu-
lation at multiple omic levels can be explored simultaneously to interrogate underlying
mechanisms.
Regarding limitations, we caution the reader that the sample size, particularly for the tran-
scriptomic data was limited, and we were unable to stratify by potential effect modifiers such
as sex.These results should therefore be considered illustrative, and the specific biological enti-
ties identified as differentially abundant should be considered exploratory.RNAseq could not
be used to quantify expression of the entire transcriptome, because leukocyte-poor blood has
insufficient cells for this technique. Therefore, we used EdgeSeq, which does not require an
RNA isolation step, but quantifies relative abundance of only 2,560 transcripts. However, the
genes included in the EdgeSeq panel were selected on the basis of their relevance to both can-
cer and the immune system, making them ideally suited to this study population. Because par-
ticipants had FN as an unscheduled emergency, their dietary intake prior to presenting in the
Emergency room may have influenced their metabolome, but this represents the scenario in
which a predictor of bacteremia would ultimately be utilized. However, we were able to pro-
vide evidence that prior antibiotic use was not influencing our results; nor was the type or site
of the initial tumor. Furthermore, within the limited sample size we were able to demonstrate
that the metabolomic profile appeared to be similar for Gram-negative and Gram-positive bac-
teremia,although it would be of interest to explore this further in the larger sample.
In conclusion, we generated metabolomic and transcriptomic predictors of bacteremia,
among FN patients without apparent infection at presentation. With overfitting as a caveat,
these predictors significantly outperformed currently-recommended risk-stratification tools,
with markedly improved specificity and perfect sensitivity. Interrogation of differentially-
abundant biomarkers revealed biologically-plausible roles in bacteremia within the setting of
FN. This is the first such study within a field that is in dire need of novel biomarkers and man-
agement strategies. Via further study in a larger sample with discovery and validation sets,
development of a biologically meaningful objective predictor that utilizes both clinical and
omics data is feasible, and will facilitate early diagnosis. This, in turn, will enable appropriate
aggressive treatment for patients predicted to have bacteremia, and appropriate conservative
treatment of those predicted not to have bacteremia.
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